GlassScriptPhysician profile
Dustin A Hebert
NPI 1295408698
$3,213.01
in general payments reported to CMS, 2019-2025
19 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $1,340 · 2023: $1,155 · 2024: $234 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.37 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $463.00 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $446.62 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $426.08 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $333.49 | 2022-2023 | Ingrezza |
| Abbvie INC. | $285.38 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.12 | 2022-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $209.65 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $172.52 | 2021-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $145.86 | 2022-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $134.08 | 2022-2023 | Hetlioz, Fanapt |
| Lundbeck LLC | $116.14 | 2021-2025 | Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $82.92 | 2022-2023 | Auvelity |
| Bausch Health US, LLC | $39.09 | 2022 | |
| Almatica Pharma LLC | $34.96 | 2022 | |
| Supernus Pharmaceuticals, INC. | $29.23 | 2023 | Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $19.10 | 2022 | |
| Bioxcel Therapeutics, INC. | $17.78 | 2023 | Igalmi |
| Acadia Pharmaceuticals INC | $13.09 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.90 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.